A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation

NCT07430397 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Factor V Leiden
Prothrombin G20210A

Interventions

DRUG: CITY-FXI
DRUG: Placebo

Sponsor

City Therapeutics